• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环孢素A脂质体与乳剂用于眼部给药的比较研究:通过响应面法(RSM)进行工艺优化及生物相容性评价

Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation.

作者信息

Li Yinglan, Guan Qingran, Xu Jie, Zhang Huaizhen, Liu Sisi, Ding Zhuang, Wang Qingpeng, Wang Zhengping, Liu Min, Zhao Yanna

机构信息

Institute of Biopharmaceutical Research, Liaocheng University, Liaocheng, Shandong 252059, People's Republic of China.

School of Geography and Environment, Liaocheng University, Liaocheng, Shandong 252059, People's Republic of China.

出版信息

Colloids Surf B Biointerfaces. 2023 May;225:113267. doi: 10.1016/j.colsurfb.2023.113267. Epub 2023 Mar 14.

DOI:10.1016/j.colsurfb.2023.113267
PMID:36940502
Abstract

Herein, cyclosporine A loaded liposomes (CsA-Lips) were fabricated aimed at improving the biocompatibility of the ophthalmic formulation and getting rid of the direct contact of ocular tissues with irritant excipients. Response surface methodology was exploited in order to investigate the influence of miscellaneous factors on the key characteristics of CsA-Lips. Ratio of EPC:CsA, ratio of EPC:Chol, and stirring speed were selected as the independent variables, while size, drug-loading content (DL), and drug-loading content (DL) loss rate were applied as the response variables. In case of the maximal lack-of-fit p-value and minimum sequential p-value, quadratic model was regarded as the fittest model to analyze the data. The correlation of independent variables with response variables was described by three-dimension surface figures. Optimized formulation for CsA-Lips was obtained with ratio of EPC:CsA set as 15, ratio of EPC:Chol set as 2, and stirring speed set as 800 rpm. The particle size of CsA-Lips was 129.2 nm after optimalization while their TEM images exhibited spherical unilamellar vesicles with clearly shell-core structure. CsA released more rapidly from CsA-Lips in comparison with self-made emulsion and Restasis®. Besides, minimum cytotoxicity of CsA-Lips was perceived via both MTT method and LDH method, indicating the excellent compatibility of the ophthalmic formulation. Simultaneously, CsA-Lips showed enhanced nonspecific internalization in the cytoplasm with a time-dose-dependent manner. In conclusion, CsA-Lips could be adhibited as the hopeful ophthalmic drug delivery system clinically for dry eye syndrome (DES).

摘要

在此,制备了载环孢素A脂质体(CsA-Lips),旨在提高眼科制剂的生物相容性,并避免眼组织与刺激性辅料直接接触。采用响应面法研究各种因素对CsA-Lips关键特性的影响。选择EPC:CsA比例、EPC:Chol比例和搅拌速度作为自变量,同时将粒径、载药量(DL)和载药量损失率作为响应变量。在失拟p值最大和顺序p值最小的情况下,二次模型被认为是分析数据的最合适模型。通过三维表面图描述自变量与响应变量之间的相关性。获得了CsA-Lips的优化配方,EPC:CsA比例设定为15,EPC:Chol比例设定为2,搅拌速度设定为800 rpm。优化后CsA-Lips的粒径为129.2 nm,其透射电镜图像显示为具有清晰核壳结构的球形单层囊泡。与自制乳剂和Restasis®相比,CsA从CsA-Lips中释放得更快。此外,通过MTT法和LDH法均观察到CsA-Lips的细胞毒性最小,表明该眼科制剂具有优异的相容性。同时,CsA-Lips在细胞质中的非特异性内化增强,呈时间-剂量依赖性。总之,CsA-Lips有望作为临床治疗干眼症(DES)的眼科药物递送系统。

相似文献

1
Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation.环孢素A脂质体与乳剂用于眼部给药的比较研究:通过响应面法(RSM)进行工艺优化及生物相容性评价
Colloids Surf B Biointerfaces. 2023 May;225:113267. doi: 10.1016/j.colsurfb.2023.113267. Epub 2023 Mar 14.
2
Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion.采用质量源于设计的方法理解环孢素眼用乳剂的关键质量属性。
Mol Pharm. 2014 Mar 3;11(3):787-99. doi: 10.1021/mp400484g. Epub 2014 Jan 24.
3
In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.新型水溶性环孢素 A 前药治疗干眼症的体内特征。
Eur J Pharm Biopharm. 2012 Apr;80(3):544-52. doi: 10.1016/j.ejpb.2011.11.017. Epub 2011 Dec 3.
4
Silk Fibroin Formed Bioadhesive Ophthalmic Gel for Dry Eye Syndrome Treatment.丝素蛋白形成的生物黏附性眼科凝胶治疗干眼症。
AAPS PharmSciTech. 2024 Apr 29;25(5):92. doi: 10.1208/s12249-024-02792-z.
5
Cyclosporine Amicellar delivery system for dry eyes.用于干眼症的环孢素无胶束递送系统。
Int J Nanomedicine. 2016 Jun 21;11:2921-33. doi: 10.2147/IJN.S107569. eCollection 2016.
6
Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.环孢素 A 眼用自乳化给药系统改善了物理化学性质,并在小鼠干眼症模型中提高了对干眼症的疗效。
PLoS One. 2019 Nov 18;14(11):e0224805. doi: 10.1371/journal.pone.0224805. eCollection 2019.
7
Stability, safety, and transcorneal mechanistic studies of ophthalmic lyophilized cyclosporine-loaded polymeric micelles.眼用冷冻干燥环孢素载药聚合物胶束的稳定性、安全性和经角膜透机理研究。
Int J Nanomedicine. 2018 Dec 5;13:8281-8296. doi: 10.2147/IJN.S173691. eCollection 2018.
8
Improving the topical ocular pharmacokinetics of lyophilized cyclosporine A-loaded micelles: formulation, in vitro and in vivo studies.提高冻干环孢素 A 载药胶束的眼部局部药代动力学:制剂、体外和体内研究。
Drug Deliv. 2018 Nov;25(1):888-899. doi: 10.1080/10717544.2018.1458923.
9
Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A.快速溶解经巩膜微针用于眼内递送达泊沙康唑。
AAPS PharmSciTech. 2024 Feb 1;25(2):28. doi: 10.1208/s12249-024-02738-5.
10
Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease.三期临床试验结局的匹配调整间接比较:OC-01(酒石酸伐尼克兰溶液)鼻喷雾剂和环孢素 A 0.05%滴眼液治疗干眼症。
J Manag Care Spec Pharm. 2022 Aug;28(8):892-902. doi: 10.18553/jmcp.2022.22005. Epub 2022 Jun 10.

引用本文的文献

1
Drug-Modified Contact Lenses-Properties, Release Kinetics, and Stability of Active Substances with Particular Emphasis on Cyclosporine A: A Review.药物修饰隐形眼镜 - 活性物质的特性、释放动力学和稳定性,特别强调环孢素 A:综述。
Molecules. 2024 Jun 1;29(11):2609. doi: 10.3390/molecules29112609.
2
Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.眼部给药系统的最新进展:眼用植入物在慢性眼病治疗中的突出地位。
Pharmaceutics. 2023 Jun 15;15(6):1746. doi: 10.3390/pharmaceutics15061746.